Jeffrey N. Simmons - 03 Mar 2025 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role
PRESIDENT, CEO AND DIRECTOR, Director
Signature
/s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons
Issuer symbol
ELAN
Transactions as of
03 Mar 2025
Net transactions value
$0
Form type
4
Filing time
05 Mar 2025, 18:49:41 UTC
Previous filing
04 Mar 2025
Next filing
11 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELAN Common Stock Award $0 +265,252 +17% $0.000000 1,802,379 03 Mar 2025 Direct F1
holding ELAN Common Stock 145,000 03 Mar 2025 By Revocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Employee Stock Option (right to buy) Award $0 +556,587 $0.000000 556,587 03 Mar 2025 Common Stock 556,587 $11.31 Direct F2
transaction ELAN Deferred Stock Units (Match) Award $0 +14,891 $0.000000 14,891 03 Mar 2025 Common Stock 14,891 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units vesting as follows: one-third vesting on March 3, 2026, one-third vesting on March 3, 2027, and the remaining vesting on March 3, 2028.
F2 Grant of stock options vesting as follows: one-third vesting on March 3, 2026, one-third vesting on March 3, 2027, and the remaining vesting on March 3, 2028.
F3 Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
F4 Deferred stock units vest December 31, 2026 and settle upon termination of employment or otherwise in accordance with the Executive Deferral and Stock Match Plan.